Celltrion/Pfizer Agree To Wait For Mid-September Inflectra Launch
Executive Summary
Celltrion Inc. and Pfizer Inc., who have been waiting to launch their biosimilar Inflectra (infliximab-dyyb) pending an ongoing legal dispute, have agreed to wait a little bit longer – now until after Sept. 15 under a stipulation with Janssen Biotech Inc., whose monoclonal antibody Remicade was the innovator on which the copycat was referenced.
You may also be interested in...
2Q Preview: GSK, Bayer, Celgene, Amgen, AZ, BMS, Sanofi, Merck, Abbvie
GSK, Bayer, Celgene, Amgen, AstraZeneca, Bristol-Myers Squibb, Sanofi, Merck & Co and AbbVie are among the pharma companies due to report second-quarter results imminently. As the financial reporting season moves into a second week, Scrip takes a look at the key things to watch for.
New $350m Site To Build Pfizer’s China Biosimilar Capacity
While some multinationals appear concerned about China's slowing economy and their business prospects in this market, others are forging ahead with major new investments, including Pfizer, which has just unveiled plans for a large biosimilars production and R&D site.
New $350m Site To Build Pfizer’s China Biosimilar Capacity
While some multinationals appear concerned about China's slowing economy and their business prospects in this market, others are forging ahead with major new investments, including Pfizer, which has just unveiled plans for a large biosimilars production and R&D site.